# Faro AI

> Structured clinical-development data models and agentic AI from protocol intent through execution.

## Why it is interesting

August 26, 2026: $37.3M Series B co-led by Merck Global Health Innovation Fund and S32, with General Catalyst returning. Company: used by six of the world’s ten largest pharmaceutical companies.

## Profile

- **Latest funding:** Series B — $37.3M (August 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $37M
- **Stage:** series-b
- **Status:** private
- **Industries:** healthtech, ai-ml, enterprise-saas
- **Coverage:** full
- **Last updated:** 2026-08-31
- **Latest funding investors:** Merck Global Health Innovation Fund, S32, General Catalyst

## Key facts

- Aug 26, 2026: $37.3M Series B; Merck GHI + S32 co-lead (company)
- General Catalyst returning with Northpond, Polaris, PTX, Zetta; Ankona new
- Company: 6 of top 10 global pharma customers
- Rebrand emphasis: Faro Health → Faro AI

## Funding history

- Series B · $37.3M · August 2026
  Source: https://faro.ai/blog/what-our-series-b-means-for-our-customers

## Investors in our directory

- https://venturecapitaltracker.com/fund/general-catalyst

## Related articles

- https://venturecapitaltracker.com/2026-faro-37-3m-series-b-merck-s32-general-catalyst
- https://venturecapitaltracker.com/2026-august-30-31-investment-news-robots-inference-world-models
- https://venturecapitaltracker.com/2026-august-vc-news

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** August 31, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/faro-ai